Pfizer Inc. (PFE) Stake Decreased by GSA Capital Partners LLP
GSA Capital Partners LLP decreased its stake in Pfizer Inc. (NYSE:PFE) by 55.7% during the second quarter, Holdings Channel reports. The firm owned 44,109 shares of the biopharmaceutical company’s stock after selling 55,361 shares during the period. GSA Capital Partners LLP’s holdings in Pfizer were worth $1,553,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Stelac Advisory Services LLC bought a new position in shares of Pfizer during the second quarter worth about $110,000. Catamount Wealth Management raised its position in shares of Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares during the last quarter. Commonwealth Financial Services LLC raised its position in shares of Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 210 shares during the last quarter. Stuart Chaussee & Associates Inc. raised its position in shares of Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,125 shares during the last quarter. Finally, Financial Management Professionals Inc. raised its position in shares of Pfizer by 21.9% in the second quarter. Financial Management Professionals Inc. now owns 5,517 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 993 shares during the last quarter. Hedge funds and other institutional investors own 69.66% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) traded down 0.06% on Monday, reaching $32.64. 3,604,536 shares of the company’s stock traded hands. Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39. The stock has a market capitalization of $197.98 billion, a price-to-earnings ratio of 28.94 and a beta of 0.86. The stock’s 50-day moving average price is $34.02 and its 200-day moving average price is $34.27.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.62 by $0.02. The company had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.56 EPS. Equities analysts predict that Pfizer Inc. will post $2.46 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 annualized dividend and a dividend yield of 3.67%. Pfizer’s payout ratio is currently 95.24%.
Several analysts have recently commented on PFE shares. Jefferies Group dropped their price objective on shares of Pfizer from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, June 20th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $54.00 price objective on shares of Pfizer in a report on Monday, June 27th. Vetr raised shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price objective on the stock in a report on Monday, June 27th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, July 20th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Pfizer in a report on Thursday, July 21st. Eleven investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. Pfizer currently has an average rating of “Buy” and an average price target of $38.59.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.